Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | ZDHHC2 | Q9UIJ5 | 3/20 | 0.61 |
| ▸ | ZDHHC20 | Q5W0Z9 | 3/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | CASP2 | P42575 | 1/20 | 0.50 |
| ▸ | THRA | P10827 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30764104 | 1.00 | ALDH1A1 (0.62) | ALDH1A1ZDHHC2ZDHHC20EGFREPHX1 | |
| SCHEMBL5362501 | 1.00 | ALDH1A1 (0.62) | ALDH1A1ZDHHC2ZDHHC20EGFREPHX1 | |
| SCHEMBL30764042 | 1.00 | ALDH1A1 (0.62) | ALDH1A1ZDHHC2ZDHHC20EGFREPHX1 | |
| SCHEMBL444527 | 1.00 | ALDH1A1 (0.62) | ALDH1A1ZDHHC2ZDHHC20EGFREPHX1 | |
| SCHEMBL9364410 | 1.00 | ALDH1A1 (0.62) | ALDH1A1ZDHHC2ZDHHC20EGFREPHX1 | |
| SCHEMBL24687428 | 1.00 | ALDH1A1 (0.62) | ALDH1A1ZDHHC2ZDHHC20EGFREPHX1 | |
| SCHEMBL5756799 | 1.00 | ALDH1A1 (0.62) | ALDH1A1ZDHHC2ZDHHC20EGFREPHX1 | |
| SCHEMBL5465005 | 1.00 | ALDH1A1 (0.62) | ALDH1A1ZDHHC2ZDHHC20EGFREPHX1 | |
| SCHEMBL1289327 | 1.00 | ALDH1A1 (0.62) | ALDH1A1ZDHHC2ZDHHC20EGFREPHX1 | |
| SCHEMBL30764058 | 1.00 | ALDH1A1 (0.62) | ALDH1A1ZDHHC2ZDHHC20EGFREPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140828-B1 | 3-AZABICYCLO¬3.1.0|HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | PFIZER LTD (GB) | 2006-08-09 | — | — | EP | disclosed |
| US-7049444-B2 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER INC. (US) | 2006-05-23 | — | — | US | disclosed |
| US-20030013875-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER, INC. (US) | 2003-01-16 | — | — | US | disclosed |
| US-20020072616-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER INC. | 2002-06-13 | — | — | US | disclosed |
| US-6313312-B1 | OPIATE RECEPTOR BINDERS; ALLERGIC DERMATITIS, PRURITUS; IRRITABLE BOWEL SYNDROME, GASTROINTESTINAL AND SKIN DISORDERS; VETERINARY MEDICINE; ANTI-ITCHING | PFIZER INC | 2001-11-06 | — | — | US | disclosed |
| EP-1140828-A1 | 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | Pfizer Limited (GB) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039089-A1 | 3-AZABICYCLO[3.1.0.] HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | PFIZER LIMITED (GB) | 2000-07-06 | — | — | WO | disclosed |
| EP-0393713-B1 | Process for the preparation of N-substituted maleimides | TOSOH CORP (JP) | 1994-06-29 | — | — | EP | disclosed |
| US-5087705-A | Heating N-substituted maleamic acid monoester in presence of acid catalyst | SHIN-DAIKYOWA PETROCHEMICAL CO., LTD. (JP) | 1992-02-11 | — | — | US | disclosed |
| US-4571418-A | Char-forming polymer, moldable composition and method | ATLANTIC RICHFIELD COMPANY (US) | 1986-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072616-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRM1, OPRK1, OPRD1 | ALDH1A1 70/4885ZDHHC2 3282/4885ZDHHC20 3354/4885 |
| US-20030013875-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRM1, OPRK1, OPRD1 | ALDH1A1 70/4885ZDHHC2 3282/4885ZDHHC20 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.